Posted by Michael Wonder on 21 Feb 2025
Green light for groundbreaking personalised cancer therapy that reprogrammes immune system
20 February 2025 - Final guidance published today recommends lisocabtagene maraleucel (Breyanzi; Bristol Myers Squibb) as an option for treating people with large B-cell lymphoma when their cancer has either not responded to initial treatment or returned within 12 months.
Just under 600 people per year in England could benefit from this new therapy, marking a significant advance in lymphoma care and representing our first recommendation of this type of treatment.
